1. Home >
  2. M&A >
  3. Merger >
  4. Mallinckrodt Acquires Endo International

M&A Deal Summary

Mallinckrodt Acquires Endo International

On March 13, 2025, Mallinckrodt acquired medical products company Endo International for 80M USD

Acquisition Highlights
  • This is Mallinckrodt’s 4th transaction in the Medical Products sector.
  • This is Mallinckrodt’s 8th largest (disclosed) transaction.
  • This is Mallinckrodt’s 1st transaction in Ireland.

M&A Deal Summary
Date 2025-03-13
Target Endo International
Sector Medical Products
Buyer(s) Mallinckrodt
Deal Type Merger
Deal Value 80M USD
Advisor(s) Goldman Sachs (Financial)
Davis Polk & Wardwell
Paul, Weiss, Rifkind, Wharton & Garrison
A&L Goodbody (Legal)

Target

Endo International

Dublin, Ireland
Endo International is a pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used to treat and manage pain, bladder cancer, prostate cancer and the early onset of puberty in children, or central precocious puberty (CPP). Endo International was incorporatted in 1920 and is based in Dublin, Ireland.

Search 214,107 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Mallinckrodt

Dublin, United Kingdom
Category Company
Founded 1867
Sector Life Science
Employees2,673
Revenue 2.2B USD (2021)
DESCRIPTION

Mallinckrodt is a specialty pharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. The company’s core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. Mallinckrodt was founded in 1867 and is based in Dublin, Ireland.

DEAL STATS #
Overall 13 of 13
Sector: Medical Products M&A 4 of 4
Type: Merger M&A Deals 1 of 1
Country: Ireland M&A 1 of 1
Year: 2025 M&A 1 of 1
Size (of disclosed) 8 of 10
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2024-08-05 Therakos

West Chester, Pennsylvania, United States

Therakos is a fully integrated extracorporeal photopheresis (ECP) delivery system for autologous immunomodulatory therapy. Therakos is based in West Chester, Pennsylvania.

Sell $925M
Mergr

Solution for

Product

Company

Legal